Article Figures & Data
Figures
- Figure 1.
Secukinumab Significantly Inhibits Radiographic Disease Progression at Week 24
IV, intravenous; mTSS, modified total Sharp score; SC, subcutaneous.
*P < .05 vs placebo (P values at week 24 adjusted for multiplicity of testing).
**P < .05 vs placebo. Reproduced with permission from D van der Heijde, MD.
- Figure 2.
Significant Radiographic Progression Inhibition With Secukinumab Regardless of Tumor Necrosis Factor Status
Full analysis set using nonparametric analysis of covariance with linear extrapolation for missing values at week 24; anti-TNF-IR: subjects with inadequate response or intolerance to previous therapy with an anti-TNF.
IR, inadequate responder; TNF, tumor necrosis factor.
Reproduced with permission from D van der Heijde, MD.
- Figure 3.
Inhibition of Radiographic Disease Progression Sustained Through Week 52 With Secukinumaba
IV, intravenous; mTSS, modified total Sharp score; SC, subcutaneous.
Radiographic disease progression was inhibited in placebo-treated subjects upon switching to secukinumab.
aX-ray completers (those subjects who had X-ray measures at baseline, week 16/24, and week 52). Reproduced with permission from D van der Heijde, MD.
Tools
FUTURE 1: Secukinumab Inhibits Radiographic Disease Progression in PsA
Permalink:
Table of contents
Cited By...
- No citing articles found.